1.Lymphoma without Lymphadenopathy.
Ashutosh JAIN ; Nilesh KUMAR ; Mahendra K JANGID ; Indrajeet Singh GAMBHIR ; Vijai TILAK
Chinese Medical Journal 2015;128(23):3256-3257
Aged
;
Bendamustine Hydrochloride
;
therapeutic use
;
Humans
;
Lymphadenopathy
;
diagnosis
;
Lymphoma
;
diagnosis
;
drug therapy
;
Male
;
Rituximab
;
therapeutic use
2.Efficacy of R±BEACOP regimen in patients with poor-prognosis lymphoma.
Fei DONG ; Yifan PANG ; Jing WANG ; Xiaoyan KE
Journal of Central South University(Medical Sciences) 2015;40(8):858-863
OBJECTIVE:
To analyze the efficacy of cyclophosphamideplus, epirubicin, vincristine, prednisone plus etoposide and/or bleomycin, with or without rituximab (R±BEACOP) regimen in patient with poor-prognosis lymphoma.
METHODS:
A total of 89 patients, who had poor-prognosis lymphoma and received at least 1 cycle of R±BEACOP regimen during 2002 to 2012, were enrolled and analyzed by a retrospective study.
RESULTS:
The rate of complete response was 62.9% (56 patients). The efficacy of Hodgkin lymphoma (HL) and T/NK NHL was better than that of other types of lymphoma. There was no significant difference in efficacy among the patients with different age, stage or international prognosis index (IPI) (all P>0.05).
CONCLUSION
R±BEACOP regimen is effective in some patients with poor prognosis, especially in HL patients. Thus, multicenter prospective study regarding the R±BEACOP regimen needs to be done to further test its efficacy.
Antineoplastic Combined Chemotherapy Protocols
;
therapeutic use
;
Bleomycin
;
therapeutic use
;
Cyclophosphamide
;
therapeutic use
;
Doxorubicin
;
therapeutic use
;
Etoposide
;
therapeutic use
;
Humans
;
Lymphoma
;
classification
;
diagnosis
;
drug therapy
;
Prednisone
;
therapeutic use
;
Procarbazine
;
therapeutic use
;
Prognosis
;
Retrospective Studies
;
Rituximab
;
therapeutic use
;
Vincristine
;
therapeutic use
3.Dose-adjusted EPOCH-R vs. R-CHOP in frontline management of Waldeyer's ring diffuse large B-cell lymphoma: a retrospective study from a single institution.
Yuanzheng LIANG ; Xindi LIU ; Jing YANG ; Henan WANG ; Yingshi PIAO ; Liqiang WEI ; Liang WANG
Chinese Medical Journal 2023;136(2):167-175
BACKGROUND:
To compare the efficacy and safety of dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin plus rituximab (DA-EPOCH-R) with standard rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in Waldeyer's ring diffuse large B-cell lymphoma (WR-DLBCL) at a single institution.
METHODS:
This retrospective study included 115 newly diagnosed patients with WR-DLBCL, of whom 68 patients received R-CHOP, and 47 patients received DA-EPOCH-R as their first-line treatment. The baseline features of the two groups were well balanced using a 1:1 propensity score matching method, and a total of 84 cases were obtained, including respective 42 cases in the R-CHOP and DA-EPOCH-R groups, for further survival and prognosis analysis. The primary objectives included progression-free survival (PFS) and overall survival (OS).
RESULTS:
During a median follow-up of 45 months, there were nine (21.4%) deaths in the R-CHOP group and two (4.8%) in the DA-EPOCH-R group. Kaplan-Meier analysis showed statistically significant improvements in PFS and OS in patients with DA-EPOCH-R compared with those treated with R-CHOP (log-rank test, P = 0.025 and P = 0.035, respectively). The 2-year PFS and OS rates in the DA-EPOCH-R group were 90.1% (95% confidence interval [CI]: 81.4-99.8%) and 95.2% (95% CI: 89.0-100.0%), respectively, and 80.5% (95% CI: 69.3-93.6%) and 90.5% (95% CI: 52.8-99.8%) in the R-CHOP group. Patients without B symptoms and elevated lactate dehydrogenase levels had a higher PFS in the DA-EPOCH-R group, with P values of 0.038 (hazard ratio [HR]: 0.11; 95% CI: 0.01-0.88) and 0.042 (HR: 0.19; 95% CI: 0.04-0.94), respectively. There were no statistically significant differences in clinical responses and treatment-related toxicities between the two groups.
CONCLUSION
Compared with patients received R-CHOP, those treated by DA-EPOCH-R had superior PFS, OS, and controlled toxicity in patients with WR-DLBCL.
Humans
;
Rituximab/therapeutic use*
;
Vincristine/therapeutic use*
;
Retrospective Studies
;
Prednisone/therapeutic use*
;
Etoposide/therapeutic use*
;
Antineoplastic Combined Chemotherapy Protocols/therapeutic use*
;
Lymphoma, Large B-Cell, Diffuse/drug therapy*
;
Cyclophosphamide/therapeutic use*
;
Doxorubicin/therapeutic use*
4.A multicenter study of rituximab-based regimen as first-line treatment in patients with follicular lymphoma.
Jianqiu WU ; Yongping SONG ; Liping SU ; Mingzhi ZHANG ; Wei LI ; Yu HU ; Xiaohong ZHANG ; Yuhuan GAO ; Zuoxing NIU ; Ru FENG ; Wei WANG ; Jiewen PENG ; Xiaolin LI ; Xuenong OUYANG ; Changping WU ; Weijing ZHANG ; Yun ZENG ; Zhen XIAO ; Yingmin LIANG ; Yongzhi ZHUANG ; Jishi WANG ; Zimin SUN ; Hai BAI ; Tongjian CUI ; Jifeng FENG
Chinese Journal of Hematology 2014;35(5):456-458
8.Treatment of pemphigus with rituximab.
Jun LI ; He-Yi ZHENG ; Yue-Hua LIU
Acta Academiae Medicinae Sinicae 2009;31(1):107-110
Pemphigus is a life-threatening autoimmune blistering disease affecting the skin and mucosa. Patients with severe pemphigus require long-term treatment with corticosteroids and other immunosuppressive drugs, which can lead to serious adverse events. Rituximab, a monoclonal antibody directed against the CD20 antigen of B lymphocytes, has been demonstrated to be effective in recalcitrant and life-threatening pemphigus.
Antibodies, Monoclonal, Murine-Derived
;
adverse effects
;
therapeutic use
;
Antigens, CD20
;
immunology
;
Humans
;
Pemphigus
;
therapy
;
Rituximab
10.Rituximab treatment strategy for patients with diffuse large B-cell lymphoma after first-line therapy: a systematic review and meta-analysis.
Yuan-Rong REN ; Yong-Dong JIN ; Zhi-Hui ZHANG ; Li LI ; Ping WU
Chinese Medical Journal 2015;128(3):378-383
BACKGROUNDRituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly prolonged event-free survival in first-line chemotherapy for patients with diffuse large B-cell lymphoma (DLBCL). But relapse and refractory DLBCL occur frequently. Although rituximab is effective, its role in salvage therapy after autologous transplant remains unclear. Maintenance therapy with rituximab in responding patients after first line chemotherapy may be a useful novel approach capable of eradicating minimal residual disease and to bring survival benefit. This systematic review and meta-analysis evaluated the effects of rituximab maintenance treatment and salvage therapy of patients with DLBCL.
METHODSWe performed a systematic review and meta-analysis of randomized controlled trials and compared rituximab maintenance or salvage therapy at relapse with observation. We searched the Cochrane Library, PubMed, EMBASE, conference proceedings, databases of ongoing trials, and references of published trials. Two reviewers independently assessed the quality of the trials and extracted data. Hazard ratios for time-to-event data were estimated and pooled.
RESULTSSeven trials including 1470 DLBCL patients were included in this systematic review and meta-analysis. Patients treated with maintenance rituximab have better overall survival (OS) and event-free survival (EFS) than patients in the observation arm, but there was no statistical significance. Patients who received rituximab salvage therapy for relapse or refractory DLBCL have statistically significantly better OS [HR of death = 0.72, 95% CI (0.55-0.94), P = 0.02], progression-free survival (PFS) [HR = 0.61, 95% CI (0.52-0.72), P < 0.05], odds ratio (OR) [RR = 1.26, 95% CI (1.07-1.47), P = 0.004] than patients in the observation arm. The rate of infection-related adverse events was higher with rituximab treatment [RR = 1.37, 95% CI = (1.14 - 1.65) P =0.001].
CONCLUSIONSAfter first-line chemotherapy, the two rituximab-combined treatment strategies, including maintenance and salvage therapies can bring survival benefit. But due to the few studies, the low methodological quality assessment and the low outcome evidence quality, it's not confirmed that the two strategies are better than normal chemotherapy regimens. More high-quality randomized controlled trials are still needed to provide reliable evidence. The higher rate of infections after rituximab therapy should be taken into consideration when making treatment decisions.
Antibodies, Monoclonal, Murine-Derived ; therapeutic use ; Humans ; Lymphoma, Large B-Cell, Diffuse ; drug therapy ; Rituximab